{"id":"infanrixtm","safety":{"commonSideEffects":[{"rate":"10–50","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"10–30","effect":"Fever"},{"rate":"10–30","effect":"Irritability or fussiness"},{"rate":"5–20","effect":"Drowsiness"},{"rate":"5–15","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infanrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses without causing disease. The vaccine primes both humoral (antibody) and cellular immunity to protect against these three bacterial infections. It is administered as part of the standard childhood immunization schedule.","oneSentence":"Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:00.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria, tetanus, and pertussis in infants and children"}]},"trialDetails":[{"nctId":"NCT01094171","phase":"PHASE4","title":"Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-03","conditions":"Poliomyelitis","enrollment":400},{"nctId":"NCT01153893","phase":"PHASE3","title":"Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Infections, Streptococcal","enrollment":105},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT01457547","phase":"PHASE4","title":"Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B, Poliomyelitis, Diphtheria","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPa"],"phase":"phase_3","status":"active","brandName":"InfanrixTM","genericName":"InfanrixTM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}